The administration of a high F IO 2 to COPD patients breathing spontaneously may result in hypercapnia, due to reversal of preexisting regional hypoxic pulmonary vasoconstriction, resulting in a greater dead space. Arterial blood gas trends have not been reported in these patients. In a 31-bed medical ICU in a teaching hospital we prospectively investigated the response of 17 CO 2 -retaining COPD patients, after acute respiratory crisis stabilization with noninvasive ventilation, to an F IO 2 of 1.0 for 40 min, after having been noninvasively ventilated with an F IO 2 of < 0.50 for 40 min. RESULTS: The mean ؎ SD baseline findings were: P aO 2 101.4 ؎ 21.7 mm Hg, P aCO 2 52.6 ؎ 10.4 mm Hg, breathing frequency 17.8 ؎ 3.7 breaths/min, tidal volume 601 ؎ 8 mL, and Glasgow coma score of 14.8 ؎ 0.3. P aO 2 significantly increased (P < .001) when F IO 2 was increased to 1.0, but there was no significant change in P aCO 2 , breathing frequency, tidal volume, or Glasgow coma score. CONCLUSIONS: During noninvasive ventilation with an F IO 2 sufficient to maintain a normal P aO 2 , a further increase in F IO 2 did not increase P aCO 2 in our CO 2 -retaining COPD patients.
Introduction
General principles guide the management of COPD patients presenting acutely to the ICU: treat precipitating factors (eg, infection); increase expiratory flow (eg, with ␤ agonist); reduce pulmonary inflammation (eg, with corticosteroid); and manage gas exchange (eg, improve oxygenation). 1 However, the administration of high F IO 2 to these patients may result in hypercapnia. [2] [3] [4] [5] [6] The reasons for this effect have been debated for many years: some believe there is a reduction in respiratory drive from the carotid chemoreceptors, and others think a worsened ventilation-perfusion matching is the cause. 7 Noninvasive ventilation (NIV) benefits patients with COPD, and it seems reasonable to expect that NIV would increase tidal volume (V T ) and improve CO 2 elimination, and thus reduce respiratory drive. 8 Published studies provide reasonable recommendations based on the effectiveness of NIV in COPD patients: reduction of treatment failure, lower mortality, fewer complications, and lower intubation rate, compared to conventional medical treatment. 9 In these patients CO 2 elimination is increased but overall ventilation-perfusion mismatch is not changed during NIV. 10 A more important effect is the unloading of the respiratory muscles, which are often close to fatigue in severe episodes of respiratory failure. 11 Crossley et al 12 concluded that CO 2 -retaining COPD patients following a period of mechanical ventilation with P aO 2 in the normal range can safely receive supplemental oxygen without retaining CO 2 or a depression of respiratory drive. A new ventilation-perfusion relationship is established during ventilation to normoxia, and it is not altered by further increasing the F IO 2 . Nevertheless, the safety of oxygen supplementation during NIV in CO 2 -retaining COPD patients is not clear.
In CO 2 -retaining COPD patients recovering from acute respiratory crisis on NIV and an F IO 2 of Յ 0.5, we studied the response of P aCO 2 to an F IO 2 of 1.0.
Methods
This study was approved by the ethics committee of Hospital Moinhos de Vento, Porto Alegre, Brazil. All subjects or the subject's legal representative gave written informed consent.
Subjects
We studied 17 COPD subjects admitted to our 31-bed medical ICU in a primary care hospital, who required NIV during treatment of acute respiratory failure (ARF). We excluded patients who were uncooperative or needed intubation. The subjects were all chronic CO 2 -retaining COPD patients, as defined by a resting P aCO 2 of Ն 45 mm Hg, previous hospital stay due to ARF-related COPD, and history of narcosis related to oxygen delivery. The diagnosis of COPD was based on history, physical examination, chest radiograph, and previous pulmonary function tests (if available). The subjects all received NIV (BiPAP Vision, Respironics, Murrysville, Pennsylvania) via oronasal mask (PerformaTrak, Respironics, Murrysville, Pennsylvania) for at least 24 hours, until stabilization of ARF.
Protocol
The high-F IO 2 measurements were conducted only after stabilization of ARF, and in our clinical judgment there was no risk of needing intubation. Before the high-F IO 2 measurements the noninvasive ventilator was calibrated with a gas flow analyzer (VT Plus-HF, Fluke Biomedical, Everett, Washington). Ventilator circuit leak was tested to calibrate the exhalation port (Whisper Swivel II, Respironics, Murrysville, Pennsylvania). The oronasal mask was positioned to permit a leak up to 20 L/min. The ventilator was set in the spontaneous/timed mode, with a PEEP of Ն 5 cm H 2 O and a peak inspiratory pressure of Ն 10 cm H 2 O, targeting and guarantying a V T or Ն 8 mL/ kg. The F IO 2 was adjusted to maintain S pO 2 of Ն 90%.
We recorded age, sex, weight, primary disease process, and predicted risk of death based on admission Acute Physiology and Chronic Health Evaluation II score. The subjects had received nothing by mouth for at least 4 hours before the high-F IO 2 measurements, were clinically stable, and remained on their usual treatment regimen. Baseline parameters for study purposes included V T , breathing frequency, the means of all cycles during minute volume (V E ) measurement, arterial blood gas values (ABL 520, Radiometer, Copenhagen, Denmark), and S pO 2 (66S, Hewlett Packard, Palo Alto, California).
The high-F IO 2 period involved only increasing the F IO 2 to 1.0: no other parameters were altered. Following 40 min at an F IO 2 of 1.0 we again measured V T , breathing frequency, V E , arterial blood gases, S pO 2 , and Glasgow coma score. F IO 2 was then returned to its previous value. The subjects were not made aware of the F IO 2 changes.
Statistical Analysis
Continuous variables are expressed as mean Ϯ SD. Differences between baseline and high-F IO 2 were analyzed with the paired t test, except for Glasgow coma score, which we analyzed with the Wilcoxon signed-rank test. All statistical analysis was performed by a statistician using statistics software (SPSS 16.0, SPSS, Chicago, Illinois). Statistical significance was set at P Ͻ .05.
Results
Among the 17 subjects, 9 were admitted due to pneumonia, and 8 were admitted due to COPD exacerbation (Table 1) . No subjects were withdrawn after enrollment. Before the high-F IO 2 measurements all the subjects were on NIV and receiving an F IO 2 between 0.25 and 0.5.
The F IO 2 increase significantly increased the mean P aO 2 , from 101.4 Ϯ 21.7 mm Hg to 290.5 Ϯ 35.7 mm Hg
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Current knowledge
High F IO 2 in spontaneously breathing patients with COPD may result in hypercapnia, due to reversal of hypoxic pulmonary vasoconstriction, resulting in increased dead space.
What this paper contributes to our knowledge
During noninvasive ventilation with an F IO 2 sufficient to maintain a normal P aO 2 , further F IO 2 increases did not increase P aCO 2 in spontaneously breathing patients with known carbon dioxide retention.
(P Ͻ .001) and the mean S pO 2 , from 94.3 Ϯ 2.2% to 98.8 Ϯ 0.8% (P Ͻ .001). There were no significant changes in any of the other measurements ( Table 2 ). The mean baseline P aCO 2 was 52.5 Ϯ 10.4 mm Hg, and the mean high-F IO 2 was 51.5 Ϯ 12.3 mm Hg. We think that a P aCO 2 increase of 5 mm Hg is the minimum clinically important change. The standard deviation of the difference between the P aCO 2 recordings at the 2 different F IO 2 levels was 4 mm Hg. For a paired sample of 17 patients, this study has a power of 99%.
Discussion
Our results support the hypothesis that increasing the F IO 2 in CO 2 -retaining COPD subjects on NIV does not cause any clinically important change in CO 2 retention.
A COPD exacerbation is defined as worsening dyspnea, cough, and/or sputum production. 13 Expiratory air-flow obstruction is worsened, the work of breathing increases, and mucus production or mucociliary clearance, or both, are altered. Spirometry shows worsened expiratory airflow obstruction, and arterial blood gas analysis usually shows an additional decrease in P aO 2 , which leads to pulmonary arterial vasoconstriction and pulmonary hypertension. 14 Supplemental oxygen is the most useful treatment in COPD-induced hypercapnic ARF, and oxygen is administered to all hypoxemic COPD patients during exacerbation. Oxygen decreases anaerobic metabolism and lactic acid production; improves brain function; decrease arrhythmias, ischemia, and pulmonary hypertension; improves right-heart function; decreases the release of antidiuretic hormone; increases the kidneys' ability to clear free water; decreases the formation of extravascular lung water (ie, pulmonary edema); improves survival; and decreases red blood cell mass and hematocrit. 14, 15 The P aCO 2 commonly rises somewhat when a patient with COPD receives supplemental oxygen, 16 but carbon dioxide narcosis due to oxygen therapy is uncommon, and patients should not be kept hypoxemic for fear that oxygen therapy could aggravate carbon dioxide retention. 17 The increase in CO 2 is probably due to a change in dead space or shift of the hemoglobin-oxygen binding curve, rather than decreased respiratory drive. 18 This expected rise should not be specifically treated unless it is excessive, resulting in a trend toward acute respiratory acidosis on serial arte- rial blood gas analyses, with central nervous system or cardiovascular side effects. Carbon dioxide narcosis may occur with excessive F IO 2 , but is much less likely with low-flow, controlled oxygen therapy. 14 Other authors have studied the behavior of P aCO 2 during increases of F IO 2 in spontaneously breathing [19] [20] [21] [22] [23] and mechanically ventilated COPD patients, 12 but P aCO 2 behavior during NIV has not previously been investigated. Sassoon et al, 19 in 17 stable COPD patients found that when the mean F IO 2 was increased to 0.94 the mean P aCO 2 increased significantly, by 4.4 mm Hg, primarily due to a 4% increase in dead space. They concluded that hyperoxia-induced hypercapnia is primarily due to impairment of gas exchange rather than to depression of ventilation.
Aubier et al 20 treated 20 COPD patients in ARF with oxygen at 5 L/min for 30 min, and measured arterial blood gases before and at the end of oxygen administration. They found only a small rise in P aCO 2 (from 61 mm Hg to 68 mm Hg), despite a large rise in P aO 2 . Although P aCO 2 rose in all the subjects, and V E fell slightly (14%), there was no correlation between the rise in P aCO 2 and the fall in ventilation, which suggests that the rise is not predominantly the result of a decrease in ventilation.
In another study, 21 the same group studied the effects of 100% oxygen on V E and arterial blood gases in COPD patients in ARF, and concluded that, despite removal of the hypoxic stimulus, the activity of the respiratory muscles maintained the V E at nearly the same value as that while breathing room air. Again, there was no correlation between P aCO 2 and V E . These data led those authors to conclude that, during ARF, although there is an initial decrease in ventilation resulting from loss of hypoxic drive, the rise in P aCO 2 following correction of hypoxia is not primarily caused by decreased ventilation.
In our patients the NIV guaranteed V T and did not permit changes in V E (10.7 Ϯ 2.4 L/min vs 10.7 Ϯ 2.6 L/min, P ϭ .96). In agreement, Hanson et al 24 and Dick et al 25 concluded that changes in physiologic dead space are sufficient to account for the hypercapnia.
Scano et al 22 studied stable COPD patients and found that respiratory drive in response to CO 2 is similar in hypercapnic COPD patients to that in normal volunteers, although less than in normocapnic COPD patients. Robinson et al 26 used the multiple inert gas elimination technique to measure ventilation, cardiac output, and the distribution of ventilation-perfusion ratio in patients with a COPD exacerbation. They found that in patients in whom P aCO 2 rises in response to 100% oxygen, ventilation decreases and alveolar dead space increases. In our study the only significant changes during high F IO 2 were increased P aO 2 and S pO 2 . There was no evidence of depression of respiratory drive due to high F IO 2 , since Glasgow coma score, V T , breathing frequency, pH, P aCO 2 , and V E were unchanged.
In patients who remained hypoxemic and/or in respiratory distress despite standard medical therapy (including oxygen), NIV has successfully supported gas exchange and prevented intubation. By counterbalancing intrinsic PEEP with applied PEEP, and by augmenting V T , NIV reduces the work of breathing and averts the circle leading to ARF. 27 NIV improves vital signs, gas exchange, and dyspnea; may obviate intubation; reduces morbidity and mortality; and shortens hospital stay in patients with moderate to severe COPD exacerbation. 9, 11 A recent metaanalysis 28 found that, compared with standard therapy, NIV reduced the need for intubation by 65% (95% CI 0.26 -0.47%), decreased in-hospital mortality by 55% (95% CI 0.30 -0.66%), and shortened hospitalization by 1.9 days (95% CI 0.0 -3.9). Thus, NIV is considered the ventilation mode of choice in hypercapnic patients with exacerbations of COPD.
Our study strengths include that it was a bedside clinical study, and the sample size calculation. Since the ventilator measurements were from a digital readout and blood gas results printed from a machine, we feel there was little chance of bias on the part of the data collectors. Our study limitations were that dead space was not measured, the sample size was small, the study was not randomized, but, since it was a physiologic study, we supposed that randomization was not needed.
Conclusions
During NIV with an F IO 2 sufficient to maintain a normal P aO 2 , a further increase in F IO 2 does not result in an increased P aCO 2 in CO 2 -retaining COPD patients, since no changes occur in V E .
